Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J-LI HCC patient-journey study
2026-525898-39-00Phase 3Authorised
- Sponsor
- ASL Napoli 1 Centro
- Start
- Aug 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of cabozantinib, atezolizumab, durvalumab, bevacizumab, regorafenib and 3 more in hepatocellular carcinoma (HCC) (2 arms), sponsored by ASL Napoli 1 Centro. Primary endpoint: Overall survival. Planned start Aug 2026; status: authorised.
02
Drugs
cabozantinibatezolizumabdurvalumabbevacizumabregorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2026-525898-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525898-39-00.